Tumor Prevention and Genetics

by Senn, Hans-Jorg

• ISBN13: 9783540440628
• ISBN10: 3540440623
• Edition: 1st
• Format: Hardcover
• Copyright: 2003-07-01
• Publisher: SPRINGER

Summary

This book presents a comprehensive update of the latest findings in oncogenetics. It also investigates the relevance of preclinical models with respect to clinical cancer prevention (primary and secondary) for major cancer types such as breast, skin, lung, prostate and colon cancer. All contributions have been written by internationally recognised experts in the field.

Table of Contents

Introduction	1	(6)
Hans-Jörg Senn
1 Latest News in Cancer Genetics
Genetic Susceptibility, Predicting Risk and Preventing Cancer	7	(12)
Paul D.P. Pharoah
Novel Approaches to Identify Low Penetrance Cancer Susceptibility Genes Using Mouse Models	19	(12)
John P. de Koning, Jian-Hua Mao, Allan Balmain
2 Assessing New Cancer Susceptibility Genes
Development of Novel Selective Cell Ablation in the Mammary Gland and Brain to Study Cell-Cell Interactions and Chemoprevention	31	(15)
Barry A. Gusterson, Wei Cui, A. John Clark
Mouse Skin as a Model for Cancer Chemoprevention by Nonsteroidal Anti-Inflammatory Drugs	46	(12)
Friedrich Marks, Gerhard Fürstenberger, Gitta Neufang, Karin Müller-Decker
Preclinical Models for Chemoprevention of Colon Cancer	58	(14)
Eugene W. Gerner, Natalia A. Ignatenko, David G. Besselsen
New Cancer Biomarkers Deriving from the NCI Early Detection Research	72	(15)
Mukesh Verma, Sudhir Srivastava
3 Update in Chemoprevention of Breast Cancer
Tamoxifen's Impact as a Preventive Agent in Clinical Practice and an Update on the STAR Trial	87	(9)
D. Lawrence Wickerham
Aromatase Inhibitors in Prevention-Data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial and the Design of IBIS-II (The Second International Breast Cancer Intervention Study)	96	(8)
Jack Cuzick
HRT Opposed by Low Dose Tamoxifen (HOT Study). Rationale and Design	104	(11)
Andrea Decensi, Arianna Galli, Umberto Veronesi
4 Secondary Prevention of Breast Cancer: The Mammography Controversy
Is Mammography Screening for Breast Cancer Really Not Justifiable?	115	(14)
Anthony B. Miller
How Reliable is the Evidence for Screening Mammography?	129	(11)
Stephen A. Feig
Political Interpretation of Scientific Evidence-Case Study of Breast Cancer Screening Policies Around the World	140	(11)
Gad Rennert
5 Chemoprevention of Skin and Lung Cancer
Skin Cancer Chemoprevention: Strategies to Save our Skin	151	(14)
Janine G. Einspahr, G. Timothy Bowden, David S. Alberts
Chemoprevention of Non-Melanoma Skin Cancer: Experience with a Polyphenol from Green Tea	165	(7)
Kenneth G. Linden, Philip M. Carpenter, Christine E. McLaren, Ronald J. Barr, Pamela Hite, Joannie D. Sun, Kou-Tung Li, Jaye L. Viner, Frank L. Meyskens
Chemoprevention of Lung Cancer: New Directions	172	(10)
Eva Szabo, Thea Kalebic
Key Issues in Lung Cancer Chemoprevention Trials of New Agents	182	(17)
Stephen Lam, Calum MacAulay, Jean C. LeRiche, Adi F. Gazdar
6 Prevention and Screening of Prostate Cancer
Prevention of Prostate Cancer	199	(13)
Claude C. Schulman, Alexandre R. Zlotta
Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELECT: The Selenium and Vitamin E Cancer Prevention Trial	212	(14)
Eric A. Klein
Problems with Prostate Specific Antigen Screening: A Critical Review	226	(9)
Hans-Peter Schmid, Ladislav Prikler, Axel Semjonow
7 Prevention and Screening of Colorectal Cancer
Genetic Predisposition as a Basis for Chemoprevention, Surgical and Other Interventions in Colorectal Cancer	235	(13)
Hansjakob Müller, Martina Plasilova, Anna Marie Russell, Karl Heinimann
Fecal Occult Blood (FOB) Screening-Trial Evidence, Practice and Beyond	248	(6)
Gad Rennert
Is FOB-Screening Really the Answer for Lowering Mortality in Colorectal Cancer?	254	(10)
Philippe Autier, Peter Boyle, Marc Buyse, Harry Bleiberg
Summary and Conclusions	264
Rudolf Morant